Get the Stockscreener App
28.61
0.21%
0.06
After Hours:
28.54
-0.07
-0.24%
Surmodics Inc stock is traded at $28.61, with a volume of 60,539.
It is up +0.21% in the last 24 hours and down -5.83% over the past month.
See More
Previous Close:
$28.55
Open:
$28.61
24h Volume:
60,539
Relative Volume:
0.45
Market Cap:
$406.58M
Revenue:
$138.20M
Net Income/Loss:
$5.52M
P/E Ratio:
75.29
EPS:
0.38
Net Cash Flow:
$9.86M
1W Performance:
+0.95%
1M Performance:
-5.83%
6M Performance:
-25.26%
1Y Performance:
+12.68%
1-Day Range:
$28.04
$28.97
1-Week Range:
$27.02
$28.97
52-Week Range:
$25.17
$42.44
Surmodics Inc Stock (SRDX) Company Profile
Name
Surmodics Inc
Sector
Industry
Phone
(952) 500-7000
Address
9924 W 74TH ST, EDEN PRAIRIE, MN
Compare SRDX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SRDX
Surmodics Inc
|
28.61 | 406.58M | 138.20M | 5.52M | 9.86M | 0.38 |
|
ABT
Abbott Laboratories
|
131.73 | 218.91B | 41.95B | 13.40B | 6.35B | 7.65 |
|
BSX
Boston Scientific Corp
|
95.05 | 139.37B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
348.12 | 134.90B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
83.37 | 106.90B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
70.60 | 41.45B | 5.72B | 4.17B | 259.90M | 6.97 |
Surmodics Inc Stock (SRDX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-07-25 | Upgrade | Lake Street | Hold → Buy |
| Jun-13-23 | Upgrade | Needham | Hold → Buy |
| Feb-13-23 | Downgrade | Needham | Buy → Hold |
| Jul-23-20 | Upgrade | Needham | Hold → Buy |
| Dec-11-19 | Downgrade | Needham | Buy → Hold |
| Nov-01-19 | Downgrade | Lake Street | Buy → Hold |
| Aug-01-19 | Reiterated | Needham | Buy |
| May-02-19 | Reiterated | Lake Street | Buy |
| May-02-19 | Reiterated | Needham | Buy |
| Feb-21-19 | Reiterated | Needham | Buy |
| May-16-18 | Reiterated | Needham | Buy |
| Mar-01-18 | Upgrade | Sidoti | Neutral → Buy |
| Feb-28-18 | Reiterated | Lake Street | Buy |
| Feb-28-18 | Initiated | Needham | Buy |
| Jul-14-17 | Initiated | Lake Street | Buy |
| Nov-21-16 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Oct-06-16 | Downgrade | Sidoti | Buy → Neutral |
| May-03-16 | Reiterated | Barrington Research | Outperform |
| Aug-06-15 | Reiterated | Barrington Research | Outperform |
| Mar-27-15 | Initiated | Dougherty & Company | Buy |
| Feb-25-14 | Initiated | Laidlaw | Buy |
| Aug-01-13 | Upgrade | Feltl & Co. | Buy → Strong Buy |
| Nov-12-12 | Reiterated | Barrington Research | Outperform |
View All
Surmodics Inc Stock (SRDX) Latest News
Surmodics' SurVeil DCB Matches IN.PACT Admiral In Efficacy With Lower Drug Dose In Global Trial - Nasdaq
Surmodics (SRDX) Publishes Promising Clinical Trial Results for SurVeil DCB | SRDX Stock News - GuruFocus
Surmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil™ Drug-Coated Balloon | SRDX Stock News - GuruFocus
Surmodics Announces Publication of TRANSCEND Trial, Highlighting Drug-Delivery Technology of its SurVeil™ Drug-Coated Balloon - Business Wire
FTC Expands Lawsuit Against GTCR Over Surmodics Acquisition - MSN
Illinois, Minnesota join FTC challenge against $627M Surmodics buyout - MedTech Dive
Illinois joins FTC suit to block GTCR’s takeover of Surmodics - Crain's Chicago Business
AG Ellison Joins Suit to Block Surmodics Acquisition - Twin Cities Business
(SRDX) Long Term Investment Analysis - news.stocktradersdaily.com
Surmodics Investigated by Block & Leviton For Potential Securities Law Violations; Investors Who Have Lost Money Are Encouraged to Contact the Firm - ACCESS Newswire
SRDX Stock Dips Despite the Launch of Pounce XL Thrombectomy System - Yahoo Finance
Surmodics launches Pounce XL for peripheral artery clot removal By Investing.com - Investing.com South Africa
Surmodics launches Pounce XL thrombectomy system - Yahoo Finance
Surmodics launches Pounce XL for peripheral artery clot removal - Investing.com Australia
Revolutionary Blood Clot Treatment: Pounce XL Shows 80% Success Rate in Just 20 Minutes - Stock Titan
Gardner Lewis Asset Management L P Raises Position in Surmodics, Inc. (NASDAQ:SRDX) - MarketBeat
Learn to Evaluate (SRDX) using the Charts - news.stocktradersdaily.com
PE Firm Hits Back Against Medical Device Coating Challenge - Law360
FTC Challenges Medical Device Coatings Deal - Medical Product Outsourcing
Zacks Research Decreases Earnings Estimates for Surmodics - Defense World
Bank of New York Mellon Corp Sells 2,966 Shares of Surmodics, Inc. (NASDAQ:SRDX) - Defense World
Here's Why You Should Retain Surmodics Stock in Your Portfolio Now - Zacks Investment Research
FTC’s First Merger Challenge Under New Leadership Signals Return to Traditional Antitrust Theories in Private Equity Deals - JD Supra
GTCR / Surmodics: Four Key Takeaways for M&A Antitrust from the First FTC Merger Challenge Under Trump - JD Supra
FTC sues to block GTCR’s ‘unlawful acquisition’ of Surmodics - Yahoo Finance
Medical Coating Market Projected To Witness Substantial Growth, 2025-2032: Freudenberg Medical Europe GmbH, - EIN News
Surmodics (NASDAQ:SRDX) Stock Rating Upgraded by Lake Street Capital - Defense World
Lake Street Upgrades Surmodics (SRDX) - Nasdaq
SRDX Stock Falls Following Plan for Legal Action Against FTC Challenge - MSN
Where are the Opportunities in (SRDX) - Stock Traders Daily
Deal Dispatch: Clock Ticks On TikTok, Raizen Explores Asset Sale, Investors Urge Walgreens To Go Private - Benzinga
FTC Sues to Block Sale of Surmodics - PlasticsToday
FTC targets GTCR in agency's first merger challenge under new Trump term - Crain's Chicago Business
FTC challenges private equity firm’s acquisition of Surmodics - MassDevice
FTC challenges $627M private equity takeover of Surmodics - MedTech Dive
Surmodics remains committed to GTCR merger despite US FTC suit - MLex
Why Surmodics Stock Is Falling On Friday - Benzinga India
Surmodics says it will defend proposed acquisition by GTCR against FTC lawsuit - pehub.com
Lake Street Upgrades SurModics to Buy From Hold, Price Target is $43 -March 07, 2025 at 08:46 am EST - Marketscreener.com
Surmodics Vows to Oppose FTC Decision to Block GTCR Deal -March 07, 2025 at 04:39 am EST - Marketscreener.com
Rhumbline Advisers Boosts Stake in Surmodics, Inc. (NASDAQ:SRDX) - Defense World
Surmodics contests FTC challenge to GTCR acquisition By Investing.com - Investing.com South Africa
Surmodics Responds To FTC Challenge, Commits To Completing Merger With GTCR - Nasdaq
US FTC sues to block private equity purchase of medical company - Reuters.com
Surmodics Says Disagrees With FTC's Decision And Remains Committed To Completing Merger with GTCR - Marketscreener.com
Surmodics contests FTC challenge to GTCR acquisition - Investing.com
Will FTC Block Surmodics' $627M Deal? Company Ready for Court Battle - StockTitan
Surmodics Issues Statement on U.S. Federal Trade Commission Challenge to Proposed Acquisition of Surmodics by Funds Affiliated with GTCR - Business Wire
FTC Challenges PE Firm's Medical Device Coatings Deal - Law360
US FTC sues to block GTCR-Surmodics deal - MLex
FTC sues to block GTCR’s $627M Surmodics acquisition - Modern Healthcare
Surmodics Inc Stock (SRDX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.32%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):